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Initial Biopsy Outcome Prediction in Korean Patients-
Comparison of a Novel Web-based Korean Prostate Cancer Risk 
Calculator versus Prostate-specific Antigen Testing
We developed and validated a novel Korean prostate cancer risk calculator (KPCRC) for 
predicting the probability of a positive initial prostate biopsy in a Korean population. Data 
were collected from 602 Koreans who underwent initial prostate biopsies due to an 
increased level of prostate-specific antigen (PSA), a palpable nodule upon digital rectal 
examination (DRE), or a hypoechoic lesion upon transrectal ultrasound (TRUS). The clinical 
and laboratory variables were analyzed by simple and multiple logistic regression analysis. 
The area under the receiver operating characteristic curve (AUC) was computed to compare 
its performance to PSA testing alone. Prostate cancer was detected in 172 (28.6%) men. 
Independent predictors included age, DRE findings, PSA level, and prostate transitional 
zone volume. We developed the KPCRC using these variables. The AUC for the selected 
model was 0.91, and that of PSA testing alone was 0.83 (P < 0.001). The AUC for the 
selected model with an additional dataset was 0.79, and that of PSA testing alone was 
0.73 (P = 0.004). The calculator is available on the website: http://pcrc.korea.ac.kr. The 
KPCRC improved the performance of PSA testing alone in predicting the risk of prostate 
cancer in a Korean population. This calculator would be a practical tool for physicians and 
patients.
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INTRODUCTION
Prostate cancer is the most common cancer and the second 
most common cause of cancer related death in the United States 
(1). Even though the incidence of prostate cancer in Korea is not 
as high as in the United States, it is swiftly increasing to reach 
the 5th most common malignancy in Korean men (2). In 2005, 
3,487 new cases and 900 deaths from prostate cancer in Korea 
were recorded (3). According to this article, the annual percent 
change of prostate cancer is 12.6%, which was calculated from 
the prostate cancer incidence 8.4 (per 100,000) in 1999 to 14.7 in 
2005. Another paper reported 4,425 new cases and 1,004 deaths 
in 2006 and 5,292 new cases and 1,107 deaths in 2007 from pros-
tate cancer in Korea (2). The age-standardized mortality rates 
have also continued to increase; 4.3 (per 100,000) in 2005, 4.5 
per 2006 and 4.6 in 2007 (2, 3). In this situation, increasing the 
information about prostate cancer provided by mass media or 
lower urinary tract symptoms motivates patients to see the phy-
sicians and get some screening tests. After an abnormal screen-
ing test patients want to seek the most objective information 
about the probability of prostate cancer diagnosis. Similarly phy-
sicians may wish to predict the probability of positive biopsy 
before biopsy is recommended (1).
  Since the introduction of prostate-specific antigen (PSA) test-
ing in 1987, serum PSA has become a useful tool in screening 
for prostate cancer (4). However, it is still difficult to differential-
ly diagnose prostate cancer from benign prostatic disease be-
cause PSA levels depend on age, prostate size, and the inflam-
matory state of the prostate (5, 6). In addition to total PSA, there 
are other clinical factors that improve the detection rate of pros-
tate cancer, such as age, digital rectal examination (DRE) find-
ings, transrectal ultrasound (TRUS) findings, PSA density (PSAD), 
PSA velocity, PSAD of transition zone volume (PSADT), percent 
of free PSA (% free PSA), and age-specific PSA (7-9). However, 
aside from % free PSA, the value of the other methods remains 
a subject of considerable debate (10).
  The tools that could precisely predict the presence of cancer 
prior to biopsy would significantly reduce the number of unnec-
essary prostate biopsies among males with elevated serum PSA 
levels, for whom it is currently difficult to determine whether a Park JY, et al.  •  Prediction for Prostate Biopsy in Korean Patients
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prostate biopsy is indicated (10). In addition, such tools could 
provide patients with their probability of prostate cancer prior 
to biopsy. Recently, some nomograms using clinical, laborato-
ry, and ultrasound parameters have been reported, and racial 
differences have been recognized as an important parameter 
that influences prostate cancer incidence (11-13). Therefore, the 
nomograms based on Western populations might not be appro-
priate for use in the Korean population due to differences in risk 
factors for prostate cancer between Asian and Western popula-
tions. Several nomograms for the Japanese population have been 
reported, but no prediction model for the Korean population 
has been published, except for a report in one Korean journal 
(10, 14, 15). Therefore, we decided to create a multiple logistic 
regression model that assigns a probability of detecting prostate 
cancer upon initial TRUS-guided biopsy in a Korean population. 
In order to determine its clinical utility at the selected probabil-
ity cutoffs, we also validated this model internally and external-
ly with our dataset and an additional dataset from the affiliated 
hospital, respectively. This model can be used as a robust tool 
to improve the prediction of prostate cancer. 
 
MATERIALS AND METHODS
Study population
Between January 2004 and December 2008, a total of 670 cases 
of TRUS-guided ten-core biopsy were performed because of 
suspicion of prostate cancer-increased level of PSA, a palpable 
nodule upon DRE, or a hypoechoic lesion upon TRUS. We ex-
cluded 15 cases with incomplete medical records, 5 cases with 
a PSA level of 1,000 ng/mL or more, and 48 cases of two or more 
repeated biopsies. Data were collected retrospectively and uni-
formly from 602 cases of initial TRUS-guided biopsy. 
Clinical factors evaluation
We chose several factors to evaluate the following important 
predictors for a positive prostate biopsy: age, DRE findings, to-
tal PSA level, free PSA level, % free PSA, TRUS findings, prostate 
volume, prostate transitional zone volume, PSAD, and PSADT. 
DRE was classified as normal or abnormal (any prostatic nodule 
or induration). Serum PSA and free PSA tests were performed 
using the automated chemiluminescent microparticle immu-
noassay analyzer Architect i2000 (Abbott Diagnostic Laborato-
ries, Abbott Park, IL, USA). TRUS findings were classified as nor-
mal or abnormal (any presence of hypoechoic lesion). The pros-
tate was measured in three dimensions, and its volume was es-
timated using a modification of the prolate ellipsoid formula 
and recorded in cm
3 (0.523 [length (cm) × width (cm) × height 
(cm)]) by TRUS (10). After identifying the transitional zone by 
TRUS, the volume was measured by the same method described 
above. PSAD and PSADT were calculated by dividing the serum 
PSA level by the calculated prostate volume and calculated tran-
sitional zone volume, respectively. A member of a urology team 
performed a DRE on all patients before the TRUS.
Transrectal ultrasonography-guided prostate biopsy
The informed consents were obtained from all of the subjects 
before the intervention. Disinfecting rectal cleaning with 10% 
povidone iodine and prophylactic antibiotics was performed 
prior to the TRUS-guided biopsy. All biopsies were performed 
with an automatic 18-gauge biopsy needle (Bard Urological Divi-
sion, Covington, GA, USA) in conjunction with a Hawk 2102EXL 
medical ultrasound scanner (BK Medical A/S, Mileparken 34, 
DK-2730 Herlev, Denmark). A minimum of ten cores, including 
samples from each case, with additional cores when indicated 
were taken from suspicious areas. The biopsy specimens were 
examined for the presence of cancer and were categorized us-
ing the Gleason score by a pathologist. 
Statistical analysis
The significance of each factor was assessed by simple logistic 
regression analysis. Multiple logistic regression analysis with a 
backward variable selection procedure was used to determine 
which factors were independent predictors of prostate cancer in 
the model-building set. PSA level, prostate volume, and prostate 
transitional zone volume were log-transformed prior to analy-
sis. A prediction equation (Park’s prediction equation) for posi-
tive biopsy was developed based on the final logistic regression 
model. Based on the receiver operating characteristic (ROC) 
curve, we selected the cut-off value for the predicted probability 
of prostate cancer, providing a high sensitivity and concomitant-
ly reducing the total number of unnecessary biopsies. We com-
pared the performance of our model with that of a model using 
the PSA level alone by calculating the area under the receiver 
operating characteristic curve (AUC) and assessing its statistical 
significance with the method proposed by Hanley and McNeil 
(16). We also compared the performance of these 2 models by 
the same method with an additional dataset of 324 patients from 
an affiliated hospital. Data are expressed as either the mean± 
standard deviation (SD), median [inter-quartile range], or per-
centage (%) of cases. All statistical outcomes are presented as 
the odds ratio (OR) and the 95% confidence interval (95% CI) 
based on a two-sided test using the SAS statistical package (Ver-
sion 9.1; SAS Institute, Cary, NC, USA). We regarded a P value < 
0.05 as statistically significant.
Ethics statement 
According to the approval of the institutional review board of 
the Korea University Guro Hospital (IRB No. GR10070-001), the 
clinical data were collected retrospectively. Informed consent 
was exempted by the board.Park JY, et al.  •  Prediction for Prostate Biopsy in Korean Patients
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RESULTS
Patients data
The characteristics of the study population are shown in Table 1. 
Adenocarcinoma of the prostate was detected upon biopsy in 
28.6% of men (172 of 602 cases). The remaining 430 cases in-
cluded 393 cases of benign prostatic hyperplasia, 34 of prostati-
tis, and 3 of high-grade prostatic intraepithelial neoplasia. Among 
the 172 cases with a positive biopsy result, the assigned Gleason 
score was 2-4 in 5 cases (2.9%), 6 in 47 cases (27%), 7 in 35 cases 
(20%), and 8-10 in 85 cases (50%). In 123 men with a serum PSA 
level or 4.0 ng/mL or less, a positive biopsy was detected in 10 
cases (8.1%), representing 5.8% of all prostate cancer cases de-
tected in the current study (10 of 172 cases). Among these 10 
cases, the assigned Gleason score was 6 in 5 cases (50%), 7 in 2 
cases (20%), and 8-9 in 3 cases (30%).
Development of the prediction model
In the simple logistic regression analysis, all of the variables list-
ed above were statistically significant predictors of prostate can-
cer upon needle biopsy (all P < 0.001) (Table 2). In the multiple 
logistic regression analysis with a backward variable selection 
procedure, the significant predictors of a positive prostate biop-
sy for all patients were age, DRE findings, PSA level, and pros-
tate transitional zone volume (Table 2). The following Park’s pre-
diction equation was developed utilizing the four independent 
risk factors for predicting a positive result of prostate cancer: 
Probability=
exp(-3.7505+0.0454×age+1.5313×log(PSA)+1.5891×DRE-1.4922×log(T-volume)
1+exp(-3.7505+0.0454×age+1.5313×log(PSA)+1.5891×DRE-1.4922×log(T-volume),
                 
where the T-volume represents the prostate transitional zone 
volume. As for continuous variables such as age, PSA, and pros-
tate transitional zone volume, the value itself was put into the 
equation. The age range was 36-89 yr, the PSA range was 0.45-
893, and the range of prostate transitional zone volumes was 
3-120. As for the categorical variable of DRE finding, 0 was used 
in the equation when normal, and 1 was used when abnormal. 
For example, a 60-yr old man with a PSA of 8 ng/mL had an ab-
normal DRE, and a prostate transitional zone volume of 15 cm
3. 
According to this equation, his risk of a positive biopsy would 
be 42%, not the 25% risk commonly quoted by a PSA level in the 
intermediate range (4-10 ng/mL) (14). Using this equation, the 
possibility for a positive biopsy ranges from 0.1% to 68.9% for 
patients with a PSA level 4 ng/mL or less.
  When 0.2642 was used as the cutoff value in the equation, 
the positive predictive value, the negative predictive value, the 
Table 1. The characteristics of the study population
Variables All cases (n = 602) Cancer group (n = 172) Non-cancer group (n = 430)
Mean age (yr) 65.67 ± 9.11 68.69 ± 7.50 64.46 ± 9.42
No. of abnormal DRE finding
   PSA (ng/mL) [range] 
   Free PSA (ng/mL) [range]
   % free PSA [range]
149 (24.8%)
  6.77 [4.41-12.19]
  1.05 [0.67-1.914]
0.16 [0.10-0.21]
94 (54.7%)
20.31 [8.72-79.24]
1.96 [0.95-7.77]
0.11 [0.07-0.16]
55 (12.8%)
5.72 [3.95-8.33]
0.92 [0.56-1.40]
0.17 [0.12-0.23]
No. of abnormal TRUS findings
   Prostate volume (cm
3)
   Prostate transitional zone volume (cm
3)
   PSAD (ng/mL/cm
3) [range]
   PSADT (ng/mL/cm
3) [range]
242 (40.0%)
43.6 ± 21.2
21.2 ± 15.3
0.17 [0.11-0.34]
0.39 [0.22-0.87]
110 (64.0%)
39.5 ± 20.5
17.5 ± 13.3 
0.61 [0.26-2.02]
1.82 [0.63-4.62]
131 (30.5%)
45.3 ± 21.2
22.8 ± 15.8
0.13 [0.09-0.21]
0.30 [0.19-0.49]
DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal ultrasound; PSAD, PSA density; PSADT, PSAD of transition zone volume.
Data are expressed as mean ± standard deviation, median [inter-quartile range], or percentage as appropriate.
Table 2. The simple and multiple logistic regression model analyzing the predictors of prostate cancer detection upon initial prostate biopsy
Variables
Simple logistic regression Multiple logistic regression*
OR (95% CI) P value OR (95% CI) P value
Age 1.06 (1.04-1.08) < 0.001 1.05 (1.02-1.08)    0.003
DRE 8.22 (5.44-12.4) < 0.001 4.90 (2.79-8.61) < 0.001
log (PSA) 4.31 (3.29-5.65) < 0.001 4.62 (3.38-6.32) < 0.001
log (free PSA) 2.74 (2.12-3.40) < 0.001
% free PSA 3.64 (1.78-7.46) < 0.001
TRUS 4.05 (2.79-5.88) < 0.001
log (P-volume) 0.46 (0.30-0.70) < 0.001
log (T-volume) 0.51 (0.39-0.68) < 0.001 0.23 (0.15-0.34) < 0.001
log (PSAD) 5.75 (4.24-7.80) < 0.001
log (PSADT) 5.04 (3.83-6.62) < 0.001
*Backward variable selection procedure was applied. OR, Odds ratio; CI, confidence interval; DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal 
ultrasound; P-volume, prostate volume; T-volume, prostate transitional zone volume; PSAD, PSA density; PSADT, PSAD of transition zone volume.Park JY, et al.  •  Prediction for Prostate Biopsy in Korean Patients
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sensitivity, and the specificity were 71%, 92%, 81%, and 87%, re-
spectively. This cutoff value would prevent 87% of unnecessary 
negative biopsies, but 19% of prostate cancer cases would be 
overlooked. When the cutoff value of 0.1 was used, the positive 
predictive value, the negative predictive value, the sensitivity, 
and the specificity were 47%, 95%, 93%, and 59%, respectively. 
When 4 ng/mL was used as the cutoff value of the PSA level, the 
positive predictive value, the negative predictive value, the sensi-
tivity, and the specificity were 34%, 92%, 94%, and 26%, respec-
tively. The ROC curve demonstrated an AUC of 0.91 for this mod-
el (95% CI, 0.88-0.93) and 0.83 for the prediction based on PSA 
alone (95% CI, 0.79-0.87), yielding significantly different values 
(P < 0.001) (Fig. 1A). 
  The accuracy of the model was determined using the valida-
tion set. When 0.1 was used as the cutoff value of the equation, 
the positive predictive value, the negative predictive value, the 
sensitivity, and the specificity were 45%, 88%, 90%, and 41%, re-
spectively. When 4 ng/mL was used as the cutoff value of the 
PSA level, the positive predictive value, the negative predictive 
value, the sensitivity, and the specificity were 39%, 86%, 98%, 
and 6%, respectively. The ROC curve was used to evaluate the 
accuracy of the predicted probability from the model, as com-
pared with the prediction based on total PSA alone (Fig. 1B). The 
AUC was 0.79 for this model (95% CI, 0.74-0.85) and 0.73 for the 
prediction based on PSA alone (95% CI, 0.68-0.79), which rep-
resents a significant difference, indicating the superiority of our 
model in differentiating between benign and malignant disease 
(P = 0.004). The receiver operating characteristic curve evaluat-
ed the accuracy of the prediction model and the other predic-
tors for the 169 patients with PSA level 4-10 ng/mL (Table 3). The 
accuracy of the predicted probability of our model was 72%. It 
was higher than those of other predictors such as PSA, % free 
PSA, PSAD, and PSADT, but the differences did not reach statis-
tical significance. Using this equation, we developed a novel Ko-
rean prostate cancer risk calculator. The calculator is available 
on the following website: http://pcrc.korea.ac.kr.
DISCUSSION
We evaluated ten risk factors associated with prostate cancer 
work up, which were commonly available to urologists in Korea. 
These risk factors included the basic clinical information (age, 
DRE findings), PSA test results, TRUS findings, and their deriva-
tives (% free PSA, prostate volume, prostate transitional zone 
volume, PSAD, and PSADT). Although TRUS is performed for 
prostate biopsy, previous studies have predicted biopsy results 
based only on clinical and laboratory findings without TRUS (1, 
17, 18), or evaluated TRUS findings or prostate volume without 
prostate transitional zone volume, PSAD, and PSADT (14, 19). 
The present study is the first assessment of these factors.
  Karakiewicz et al. (1) have shown that the combination of 
age, DRE findings, PSA and % free PSA yields an AUC of 77% in 
Table 3. Comparison of nomogram results and other predictors when PSA level 4-10 
ng/mL by ROC analysis
Model Area under curve 95% CI
Our model 0.72 0.62-0.82
PSA  0.66 0.56-0.76
% free PSA 0.61 0.50-0.72
PSAD  0.66 0.55-0.76
PSADT  0.66 0.56-0.76
PSA, prostate-specific antigen; PSAD, PSA density; PSADT, PSAD of transition zone 
volume.
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Fig. 1. Receiver operating characteristics curve for our model and prostate specific antigen (A) in 602 patients who underwent initial prostate biopsies (P < 0.001), (B) in 324 
patients from additional dataset for the external validation (P = 0.004).
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prediction of prostate cancer on needle biopsy for the patients 
whose PSA level was not greater than 50 ng/mL. Most urologists 
in Korea perform PSA testing and TRUS due to the lower medi-
cal costs. On the contrary, free PSA is not covered by the Nation-
al Health Insurance in Korea when total PSA level is below 4 ng/ 
mL. As a result, free PSA is not so widely available for the new 
patients whose total PSA level is uncertain. Therefore, TRUS vari-
ables would be more practical than % free PSA for the prostate 
cancer predictor in Korea. Suzuki et al. developed and validated 
an initial biopsy nomogram predicting prostate cancer in Japa-
nese patients which yielded a predictive accuracy of about 80% 
(14). They used age, DRE findings, PSA, % free PSA and prostate 
volume measured by TRUS as significant predictors. The accu-
racy of nomogram in this study is similar to our results although 
the numbers of the variables are more than four, which means 
that the prediction performance is not so efficient. 
  Including these previous articles mentioned above, many 
studies have investigated the predictive model for prostate can-
cer using age, abnormal DRE findings, and elevated total PSA 
level (1, 14, 15, 18). However, the efficacy of prostate transitional 
zone volume in the predictive model has not been mentioned 
yet. It has been reported that a larger volume of the prostate may 
predict a lower possibility of prostate cancer (14). Therefore, 
large prostate volume may be a protective factor for detecting 
prostate cancer. Considering OR of prostate and prostate tran-
sitional zone volume in simple and multiple logistic regression 
in this study and that benign prostatic hyperplasia is almost ex-
clusively the result of hyperplasia of the transition zone (20), the 
volume of the prostate transitional zone can be potentially a 
more protective factor. There is a report supporting the hypoth-
esis that PSADT is more accurate in predicting a positive biopsy 
than PSAD for patients with PSA levels between 4.1 ng/mL and 
10.0 ng/mL (7). The issue has been also investigated in Korea. 
Kang and colleagues assessed that PSADT might be more use-
ful than % free PSA or PSAD for patients with the same PSA lev-
els (21).
  According to the results of the multiple logistic regression 
analysis, the independent factors associated with a positive bi-
opsy were more advanced age, abnormal DRE findings, elevat-
ed total PSA level, and smaller prostate transitional zone vol-
ume. We used these factors to develop a predictive model for 
detecting prostate cancer in order to reduce the number of un-
necessary prostate biopsies. Using a cancer probability cutoff 
level of 10%, we predicted a reduction in the number of unnec-
essary biopsies by 59%, while maintaining a sensitivity of 93%. 
With the dataset for external validation, if we decide that only 
those patients with 10% predicted probability of prostate cancer 
will undergo a biopsy, then our model captures 90% of all pros-
tate cancer cases (sensitivity), while sparing 41% of patients with-
out prostate cancer from undergoing an unnecessary procedure 
(specificity). On the other hand, with the cutoff value of 4 ng/mL 
PSA, 6% of unnecessary negative biopsies would be prevented, 
but 2% of prostate cancer cases would be overlooked. Consider-
ing the potential complication with TRUS-guided biopsy, efforts 
should be directed toward avoiding unnecessary biopsies as well 
as preventing failure to diagnose cancer. In addition, using this 
equation when the significant predictors are present, the possi-
bility for a positive biopsy ranges up to about 70% in case of a 
PSA level 4 ng/mL or less. From this point of view, PSA alone 
may not be a proper tool for deciding whether the biopsy should 
be performed as indicated by other investigators (9, 17).
  Our grade distribution had a high proportion of Gleason score 
7 or higher. This may be due to the fact that we included patients 
with PSA levels up to 900 ng/mL. However, the detection rates 
of previous studies were between 20% and 40%, which was not 
so different from 28.6% of our result (10-15). Moreover, most of 
these studies did not describe the Gleason score distribution, 
which made the direct comparison impossible. Song et al. (22) 
reported that, unlike western population, proportion of patients 
with Gleason scores 7 or higher was more than half of each sub-
group throughout the clinical stages and PSA ranges and con-
cluded that prostate cancers arising in Korean men exhibit poor 
differentiation regardless of the initial serum PSA level or clinical 
stage at presentation. Our grade distribution might be the reflec-
tion of the racial difference in prostate cancer characteristics.
  The limitation of Park’s prediction equation is that it is not 
simple enough for patients to use. For this reason, we developed 
a novel KPCRC and made it available on the web. Now that in-
ternet access is easily available throughout Korea, this web-based 
calculator can be used by both physicians and patients without 
any difficulty. For the patients with very high PSA level, we de-
cided the range of PSA levels up to 900 ng/mL. With the calcula-
tor on the website, they can calculate their results at home. On 
the contrary, this model may not be directly applicable to Kore-
an men living outside of Asia. However, given that nomograms 
developed in Western countries cannot be directly applied to 
the Asian male population (14), the KPCRC can be used to pre-
cisely predict the probability of a positive prostate biopsy for the 
selected population. In the present study, we showed that the 
KPCRC improved the performance of PSA testing alone in pre-
dicting the risk of prostate cancer in a Korean population. This 
is the first study to address a web-based prediction model using 
Korean population data. The model will provide physicians and 
patients in Korea with information that can be used in deciding 
whether to undergo prostate biopsy.
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Initial Biopsy Outcome Prediction in Korean Patients-Comparison of a Novel  
Web-based Korean Prostate Cancer Risk Calculator versus Prostate-specific Antigen 
Testing
Jae Young Park, Sungroh Yoon, Man Sik Park, Dae-Yeon Cho, Hong-Seok Park, Du Geon Moon, and Duck Ki Yoon
We developed and validated a novel Korean prostate cancer risk calculator (KPCRC) for predicting the probability of a positive 
initial prostate biopsy in a Korean population. Data were collected from 602 Koreans who underwent initial prostate biopsies. The 
clinical and laboratory variables were analyzed by simple and multiple logistic regression analysis. The area under the receiver 
operating characteristic curve (AUC) was computed to compare its performance to PSA testing alone. Prostate cancer was detected 
in 172 (28.6%) men. Independent predictors included age, DRE findings, PSA level, and prostate transitional zone volume. The 
AUC for the selected model was 0.91, and that of PSA testing alone was 0.83. The AUC for the selected model with an additional 
dataset was 0.79, and that of PSA testing alone was 0.73. The KPCRC improved the performance of PSA testing alone in 
predicting the risk of prostate cancer in a Korean population.